Valentin J P, Qiu C, Muldowney W P, Ying W Z, Gardner D G, Humphreys M H
Division of Nephrology, San Francisco General Hospital, California 94110.
J Clin Invest. 1992 Oct;90(4):1302-12. doi: 10.1172/JCI115995.
Experimental nephrotic syndrome results in sodium retention, reflecting, at least in part, an intrinsic defect in renal sodium handling in the distal nephron. We studied the relationships among plasma atrial natriuretic peptide (ANP) concentration, sodium excretion (UNaV), and urinary cyclic GMP excretion (UcGMPV) in vivo, and the responsiveness of isolated glomeruli and inner medullary collecting duct (IMCD) cells to ANP in vitro, in rats with adriamycin nephrosis (6-7 mg/kg body weight, intravenously). 3-5 wk after injection, rats were proteinuric and had a blunted natriuretic response to intravenous infusion of isotonic saline, 2% body weight given over 5 min. 30 min after onset of the infusion, plasma ANP concentrations were elevated in normals and were even higher in nephrotics. Despite this, nephrotic animals had a reduced rate of UcGMPV after the saline infusion, and accumulation of cGMP by isolated glomeruli and IMCD cells from nephrotic rats after incubation with ANP was significantly reduced compared to normals. This difference was not related to differences in binding of 125I-ANP to IMCD cells, but was abolished when cGMP accumulation was measured in the presence of 10(-3) M isobutylmethylxanthine or zaprinast (M&B 22,948), two different inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Infusion of zaprinast (10 micrograms/min) into one renal artery of nephrotic rats normalized both the natriuretic response to volume expansion and the increase in UcGMPV from the infused, but not the contralateral, kidney. These results show that, in adriamycin nephrosis, blunted volume expansion natriuresis is associated with renal resistance to ANP, demonstrated both in vivo and in target tissues in vitro. The resistance does not appear related to a defect in binding of the peptide, but is blocked by PDE inhibitors, suggesting that enhanced cGMP-PDE activity may account for resistance to the natriuretic actions of ANP observed in vivo. This defect may represent the intrinsic sodium transport abnormality linked to sodium retention in nephrotic syndrome.
实验性肾病综合征会导致钠潴留,这至少部分反映了远端肾单位在处理钠方面存在内在缺陷。我们研究了阿霉素肾病大鼠(静脉注射6 - 7 mg/kg体重)体内血浆心钠素(ANP)浓度、钠排泄(UNaV)和尿中环鸟苷酸排泄(UcGMPV)之间的关系,以及体外分离的肾小球和髓质内层集合管(IMCD)细胞对ANP的反应性。注射后3 - 5周,大鼠出现蛋白尿,对静脉输注等渗盐水(5分钟内给予2%体重)的利钠反应减弱。输注开始30分钟后,正常大鼠的血浆ANP浓度升高,肾病大鼠的更高。尽管如此,肾病动物在输注盐水后的UcGMPV速率降低,与正常大鼠相比,肾病大鼠的分离肾小球和IMCD细胞在与ANP孵育后cGMP的积累显著减少。这种差异与125I - ANP与IMCD细胞的结合差异无关,但当在存在10(-3) M异丁基甲基黄嘌呤或扎普司特(M&B 22,948)(两种不同的环核苷酸磷酸二酯酶(PDEs)抑制剂)的情况下测量cGMP积累时,这种差异消失。向肾病大鼠的一侧肾动脉输注扎普司特(10微克/分钟)可使对容量扩张的利钠反应以及输注侧而非对侧肾脏的UcGMPV增加恢复正常。这些结果表明,在阿霉素肾病中,容量扩张性利钠减弱与肾脏对ANP的抵抗有关,这在体内和体外靶组织中均得到证实。这种抵抗似乎与该肽的结合缺陷无关,但被PDE抑制剂阻断,这表明增强的cGMP - PDE活性可能是体内观察到的对ANP利钠作用抵抗的原因。这种缺陷可能代表了与肾病综合征中钠潴留相关的内在钠转运异常。